Ceftobiprole
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Staphylococcal Skin Infections
Conditions
Staphylococcal Skin Infections, Streptococcal Infections
Trial Timeline
Jun 1, 2007 → Sep 1, 2007
NCT ID
NCT01026740About Ceftobiprole
Ceftobiprole is a phase 1 stage product being developed by Basilea Pharmaceutica for Staphylococcal Skin Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01026740. Target conditions include Staphylococcal Skin Infections, Streptococcal Infections.
What happened to similar drugs?
4 of 5 similar drugs in Staphylococcal Skin Infections were approved
Approved (4) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00965042 | Phase 1 | Completed |
| NCT00771524 | Phase 1 | Completed |
| NCT00771719 | Phase 1 | Terminated |
| NCT01026740 | Phase 1 | Completed |
Competing Products
20 competing products in Staphylococcal Skin Infections